Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Lymphocytic, Small|Lymphoma, Mantle-Cell|Waldenstrom Macroglobulinemia|Ritcher's Transformation, Syndrome
DRUG: Pirtobrutinib
This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.